Tag Archives: FDA

Parents Warn of Possible Psychiatric Drug Dangers

Darkness hung over Charleston Harbor as Matthew Steubing parked his Ford pickup truck on the aging bridge and left a note on the seat beside his Bible. He put on a life jacket and began to climb — up, up, into the span’s superstructure. Then, he jumped.

His parents were waiting for Matthew to arrive home in Winchester, Va., when they received the news on July 18, 2003. Their 18-year-old son plunged more than 160 feet from the Silas Pearman Bridge before slamming into the Cooper River. He was gone. “Our world blew apart,” his mother, Celeste Steubing, said. “We couldn’t imagine this happening because this wasn’t Matthew. … It made no sense.” Matthew, the youngest of six children, had been a vibrant kid, happy and full of life. But after a rough patch in his senior year of high school left him feeling down, a psychologist suggested he would benefit from the antidepressant drug Lexapro. He soon became withdrawn and anxious, his parents recalled during a recent visit to Charleston. Matthew committed suicide just nine weeks after starting on the drug. Only later did his family learn that antidepressants carry a heightened risk of suicide in children, the Steubings said. The Steubings have made it their mission to warn other parents about the hidden dangers of psychiatric drugs. To that end, Celeste Steubing was featured in the recently released documentary, “Dead Wrong,” produced by the Los Angeles-based Citizens Commission on Human Rights.

Disciplined doctors receiving pharmaceutical funds

About 48 of the more than 1,730 California doctors who received money from pharmaceutical companies over the past 21 months have been the subject of disciplinary action, a database compiled by the investigative news organization ProPublica found. ProPublica found that the seven drug companies paid $6.7 million to 290 doctors who faced disciplinary action or other regulatory sanctions in various states. San Francisco psychiatrist Karin Hastik, for example, took $168,658 in speaking and consulting fees from Eli Lilly, AstraZeneca and GlaxoSmithKline since 2009. But in May, the Medical Board of California placed Hastik on probation for negligence, prescribing drugs without prior examination, and failing to keep adequate records about a patient she had been caring for since 2000. Hastik did not return calls for comment.

Justice to Pharma: “Do the Perp Walk!”

Former GSK counsel is the first target in government’s executive-liability crackdown. Could J&J be next? The US Department of Justice filed criminal charges last week against Lauren Stevens, a former VP and assistant general counsel at GlaxoSmithKline. Going after pharma execs marks a seismic shift in the government’s efforts to stem the tide of fraud and other illegal pharma marketing practices, which a raft of billion-dollar settlements have so far failed to end. Stevens is charged with obstruction of an investigation, concealment and falsification of documents, and making false statements to the FDA in its 2002 investigation of off-label promotion of the antidepressant Wellbutrin for weight loss, an indication for which it has never been approved but has shown some clinical benefit. The DoJ says that it has evidence, in the vast paper and electronic documentation turned over by GSK, showing that Stevens hid and otherwise misled the agency about some 1,000 instances of GSK-paid doctors promoting Wellbutrin for weight loss to other doctors.

ADHD’s Rapid Rise: 5 Theories [And One Answer]

by CCHR—THE WEEK posted a pretty good article called “ADHD’s Rapid Rise: 5 Theories” — pretty good because though several of their theories may play some part in why so many kids are diagnosed ADHD, they never quite nail the answer. So we did. Adding to their 5 points of various theories, we (CCHR) present you with point number 6: The actual answer.

Seven Ways Medical Conflicts of Interest are Disguised

The American Psychiatric Association, in its 240 page guide to its May annual meeting, “forgot” to mention the conflicts of interest of its own president Alan Schatzberg, MD. It had to print them on the newsletter circulated the third day of the meeting. Nor were names even alphabetized for easy information retrieval. (Schatzberg is financially linked to Eli Lilly, GSK, Merck, Pfizer, Forest, Takeda, Sanofi-Aventis and eight other companies.)